Literature DB >> 12478124

Transitional cell carcinoma involving the prostate: a clinicopathological retrospective study of 76 cases.

B Njinou Ngninkeu1, F Lorge, P Moulin, J Jamart, P J Van Cangh.   

Abstract

PURPOSE: We reviewed the degree to which extension from transitional cell carcinoma into the prostate affects survival. We also compared whether prostatic stromal invasion occurring via direct extension through the bladder wall differs from stromal invasion arising intraurethrally.
MATERIALS AND METHODS: A total of 76 men who underwent radical cystectomy for transitional cell carcinoma also had prostate involvement. Patients were separated into group 1-18 with primary bladder tumor extending transmurally through the bladder wall to invade the prostate and group 2-58 with prostate involvement arising from within the prostatic urethra. In the latter group the degree of prostate invasion was classified as urethral mucosal involvement, ductal/acinar involvement and stromal invasion.
RESULTS: The 5-year overall survival and recurrence-free rate were 22% and 28% in group 1 versus 43% and 45% in group 2, respectively. In group 2 survival rates were similar in those with prostatic urethral and ductal tumors (without stromal invasion). Five-year overall survival rates without and with stromal invasion were 49% and 25%, respectively (p = 0.024). Prostate involvement decreased survival, which varied according to primary bladder stages (Pis, P1, P2a/b and P3a/b, p = 0.004) or superficial (Pis, Pa and P1) and muscle invasive (P2a/b and P3/b, p = 0.045), disease in 2 groups. Those with positive lymph nodes experienced poorer outcomes in each group. The 5-year overall survival rate in the 19 men with positive lymph nodes was 13% and it was 44% with negative lymph nodes (p = 0.034). The major prognostic factors were age, degree of prostate invasion and lymph node involvement.
CONCLUSIONS: The invasion pathways of prostate invasion in patients with transitional cell bladder carcinoma have a statistically significant prognostic role in survival. Transitional cell carcinoma of the bladder extending into the prostate through the bladder wall and bladder carcinoma that did not directly infiltrate the prostate through the bladder wall are 2 distinct clinicopathological entities that should not be included in the same staging grade.

Entities:  

Mesh:

Year:  2003        PMID: 12478124     DOI: 10.1097/01.ju.0000042810.43380.36

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  9 in total

1.  CUA guidelines on the management of non-muscle invasive bladder cancer.

Authors:  Wassim Kassouf; Samer L Traboulsi; Girish S Kulkarni; Rodney H Breau; Alexandre Zlotta; Andrew Fairey; Alan So; Louis Lacombe; Ricardo Rendon; Armen G Aprikian; D Robert Siemens; Jonathan I Izawa; Peter Black
Journal:  Can Urol Assoc J       Date:  2015-10-13       Impact factor: 1.862

2.  Transurethral prostate biopsy before radical cystectomy remains clinically relevant for decision-making on urethrectomy in patients with bladder cancer.

Authors:  Koji Ichihara; Hiroshi Kitamura; Naoya Masumori; Fumimasa Fukuta; Taiji Tsukamoto
Journal:  Int J Clin Oncol       Date:  2011-11-08       Impact factor: 3.402

3.  Clinical outcomes of urothelial carcinoma of the prostate detected in radical cystectomy specimens.

Authors:  Koji Ichihara; Naoya Masumori; Hiroshi Kitamura; Tadashi Hasegawa; Taiji Tsukamoto
Journal:  Int J Clin Oncol       Date:  2012-12-19       Impact factor: 3.402

4.  Superficial bladder cancer: an update on etiology, molecular development, classification, and natural history.

Authors:  Erik Pasin; David Y Josephson; Anirban P Mitra; Richard J Cote; John P Stein
Journal:  Rev Urol       Date:  2008

5.  Usefulness of transurethral biopsy for staging the prostatic urethra before radical cystectomy.

Authors:  Friedrich Carl von Rundstedt; Seth P Lerner; Guilherme Godoy; Gilad Amiel; Thomas M Wheeler; Luan D Truong; Steven S Shen
Journal:  J Urol       Date:  2014-08-12       Impact factor: 7.450

Review 6.  Current Perspectives on the Diagnosis and Management of Primary Urethral Cancer: A Systematic Review.

Authors:  M Ryan Farrell; Jonathan T Xu; Alex J Vanni
Journal:  Res Rep Urol       Date:  2021-06-01

7.  Double cocktail immunostains with high molecular weight cytokeratin and GATA-3: useful stain to discriminate in situ involvement of prostatic ducts or acini from stromal invasion by urothelial carcinoma in the prostate.

Authors:  Junghye Lee; Youngeun Yoo; Sanghui Park; Min-Sun Cho; Sun Hee Sung; Jae Y Ro
Journal:  J Pathol Transl Med       Date:  2020-02-10

8.  The secondary tumor of the prostate derived from upper tract urothelial carcinoma: An autopsy case.

Authors:  Keisuke Goto; Takahiro Kambara; Yoshito Kagiyama; Kenshiro Takemoto; Kohei Kobatake; Kenichiro Ikeda; Shogo Inoue; Tetsutaro Hayashi; Yukio Takeshima; Jun Teishima
Journal:  IJU Case Rep       Date:  2021-08-31

9.  Low grade urothelial carcinoma mimicking basal cell hyperplasia and transitional metaplasia in needle prostate biopsy.

Authors:  Julian Arista-Nasr; Braulio Martinez-Benitez; Leticia Bornstein-Quevedo; Elizmara Aguilar-Ayala; Claudia Natalia Aleman-Sanchez; Raul Ortiz-Bautista
Journal:  Int Braz J Urol       Date:  2016 Mar-Apr       Impact factor: 1.541

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.